Antiplatelet therapy in peripheral arterial disease

Current Drug Targets. Cardiovascular & Haematological Disorders
Wilbert S Aronow

Abstract

Antiplatelet therapy significantly reduces the incidence of vascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with peripheral arterial disease (PAD) and intermittent claudication, in patients undergoing peripheral grafting, in patients undergoing peripheral angioplasty, and in patients with carotid disease. Aspirin, aspirin plus dipyridamole, ticlodipine, and clopidogrel have been shown to be efficacious in the treatment of PAD. Data from the Clopidogrel versus Aspirin in Patients at Risk for Ischaemic Events (CAPRIE) trial demonstrated in 11,592 patients with PAD that patients randomized to clopidogrel 75 mg daily had a 24% significant (p=0.0028) reduction in vascular death, nonfatal myocardial infarction, and nonfatal stroke than patients randomized to aspirin 325 mg daily. These data favor the use of clopidogrel in patients with PAD.

Citations

Nov 13, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Alejandro Zimman, Eugene A Podrez
Oct 29, 2010·Human Genomics and Proteomics : HGP·Ofer EidelmanHarvey B Pollard
Jul 10, 2007·Metabolism: Clinical and Experimental·Andreas RitschJoseph R Patsch
Jun 30, 2009·Journal of Vascular Surgery·Jean-Jacques MouradUNKNOWN ELLIPSE scientific committee and study investigators
Aug 10, 2013·Nature Reviews. Immunology·Johnathan CantonSergio Grinstein
Sep 21, 2006·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Hassan M IsmailDaniel Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.